Company intelligence / Profile preview
Beijing Suncadia Pharmaceuticals Co., Ltd.
- Ownership
- Private
- Development stage
- Other
Overview
Beijing Suncadia Pharmaceuticals is an active subsidiary of Jiangsu Hengrui Medicine Co., Ltd. Founded in Beijing's Yizhuang district in 2019, it focuses on innovative drug R&D targeting cardiovascular, metabolic, and nervous system diseases. Its pipeline includes monoclonal antibodies such as SHR1918 (ANGPTL3 inhibitor) now in Phase III for hyperlipoproteinaemia type II and small molecules like HRS8179 targeting SUR1 for brain edema currently at the Phase II/III stage. The company has conducted over thirty clinical trials with a focus on high unmet medical needs.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small molecule drugsMonoclonal antibodiesAntibodies in general
- Industry
- Pharma
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Beijing Suncadia Pharmaceuticals Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Suncadia Pharmaceuticals Co., Ltd..